{
  "meta": {
    "title": "Hypothalamus_And_Pituitary_Drugs",
    "url": "https://brainandscalpel.vercel.app/hypothalamus-and-pituitary-drugs-33bb152b.html",
    "scrapedAt": "2025-11-30T11:19:50.834Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Prostate carcinoma</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Anovulatory infertility</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Central Diabetes insipidus</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Variceal bleeding</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">On binding of drug  \"X\" to a GPCR receptor, there is increased production of inositol triphosphate (IP3) in the basophilic cells of the anterior pituitary. Administration of this drug every 90 minutes is most likely to be beneficial in the treatment of which of the following conditions?</span></p>",
      "unique_key": "DT1166405",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166405,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Pulsatile administration of GnRH stimulates the pituitary to secrete FSH and LH, which promotes ovulation in women with hypogonadotropic anovulatory infertility.</p>\r\n<ul>\r\n<li>GnRH acts via <strong>Gq protein-coupled receptors</strong> &rarr; activation of <strong>IP3/DAG pathway</strong> in basophilic cells of the anterior pituitary.</li>\r\n<li>Pulsatile GnRH administration stimulates <strong>FSH &amp; LH release</strong>, correcting ovulation in hypogonadotropic hypogonadism.</li>\r\n<li>Continuous administration causes <strong>downregulation/desensitisation</strong> of GnRH receptors &rarr; suppresses FSH/LH &rarr; used for hormone-sensitive cancers.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100130c6037d-80bf-4128-ac2e-e9259e770aca.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prostate carcinoma (Option A):</strong> Treated with continuous GnRH agonists (e.g., leuprolide), which downregulate pituitary GnRH receptors and suppress gonadotropins.</p>\r\n<p><strong>Central Diabetes Insipidus (Option C):</strong> Managed with desmopressin, an ADH analogue that increases cAMP via V2 receptors in the kidney, not via IP3.</p>\r\n<p><strong>Variceal bleeding (Option D):</strong> Treated with octreotide, which reduces splanchnic blood flow via inhibition of cAMP, not by stimulating IP3 in the pituitary.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403221924d656-780c-4f68-8f5a-c91e6a7e2bbb.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403220bdc22e3-2fc6-4c5e-bf5c-26b9dc3493b2.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325740d02e5-5895-4711-90cd-58a91bed52e4.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322ff766f77-6050-4d28-89ed-26ce9c78357f.jpg\">\r\n<p>GPCR pathway examples</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322dcc30664-2505-45dc-864a-b7a0f8f350a4.jpg\">",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Bromocriptine</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Desmopressin</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Demeclocycline</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Tesamorelin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30-year-old man complains of increased thirst and frequent urination after sustaining a head trauma. Neurologic examination shows no abnormalities. Serum sodium concentration is 152 mEq/L. Which of the following drugs is most appropriate for this patient's condition?</span></p>",
      "unique_key": "DT1166408",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166408,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical picture of polyuria, polydipsia, and hypernatremia following head trauma is characteristic of <strong>central diabetes insipidus (CDI)</strong> due to <strong>ADH deficiency</strong> from hypothalamic or pituitary damage.</p>\r\n<ul>\r\n<li><strong>Desmopressin</strong> is a synthetic analogue of vasopressin that selectively acts on <strong>V2 receptors</strong> in the kidney, leading to increased water reabsorption via <strong>aquaporin-2</strong> channel insertion in the collecting ducts.</li>\r\n<li>It effectively corrects the <strong>water diuresis</strong> seen in CDI and is the treatment of choice.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001e333031c-32a3-40d9-b886-22df168eef9e.png\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322b5650cab-5751-446b-bf51-68b49b17cd30.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403225099856c-e5da-4d49-9235-e81d53ef9c91.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Bromocriptine (Option A):</strong> Dopamine D2 agonist used to treat <strong>hyperprolactinemia</strong> and <strong>Parkinsonism</strong>; has no role in ADH-related disorders.</p>\r\n<p><strong>Demeclocycline (Option C):</strong> Tetracycline derivative used in <strong>SIADH</strong> due to its ADH antagonist effect; <strong>worsens DI</strong> by further reducing ADH action.</p>\r\n<p><strong>Tesamorelin (Option D):</strong> <strong>GHRH analogue</strong> used in HIV-associated lipodystrophy; not used for any form of DI.</p>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Atosiban</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Bromocriptine </span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Mecasermin </span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Somatropin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 2-year-old boy with failure to thrive is found to have an inactivating mutation of the growth hormone receptor gene. Which of the following agents is most appropriate to improve his metabolic function and support growth?</span></p>",
      "unique_key": "DT1166413",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166413,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Mecasermin </strong>is a<strong> recombinant human IGF-1 analogue </strong>approved for use in children with<strong> severe primary IGF-1 deficiency</strong>, particularly when caused by<strong> inactivating mutations of the GH receptor.</strong></p>\r\n<p>In such cases, somatropin is ineffective as it acts via GH receptors to stimulate IGF-1 synthesis. Mecasermin directly replaces IGF-1, thereby restoring its anabolic and growth-promoting actions.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510015b2b423a-67a2-49a6-95fc-0285965caa22.png\">\r\n<p><strong>(other options ruled out)</strong></p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Schizophrenia</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Tremor</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Recent Covid19 infection</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Recent neurosurgery</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman presents with amenorrhea, galactorrhea, and infertility. She has started on oral bromocriptine therapy. Before initiating the drug, which of the following histories should be specifically elicited due to their relevance in assessing contraindications?</span></p>",
      "unique_key": "DT1166414",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166414,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Bromocriptine</strong> is a<strong> dopamine receptor agonist </strong>used for treating <strong>hyperprolactinemia-related disorders </strong>such as<strong> amenorrhea and galactorrhea. </strong></p>\r\n<ul>\r\n<li>Because of its <strong>central dopaminergic activity, bromocriptine </strong>is contraindicated in patients with a history of<strong> schizophrenia </strong>or other<strong> psychotic disorders.</strong></li>\r\n<li>It acts by inhibiting prolactin secretion through activation of D<sub>2</sub> receptors in the hypothalamus and pituitary. The drug can cross the blood-brain barrier and may exacerbate psychotic symptoms due to its dopamine agonist effect.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001f4fcb732-e765-4ad8-8a65-d0ccf5abc0c7.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Tremor (Option B):</strong> Not a contraindication. Tremor may occur at higher doses, but it is not a major concern in routine use.</p>\r\n<p><strong>Recent COVID-19 infection (Option C):</strong> Not directly relevant unless associated with severe cardiovascular complications.</p>\r\n<p><strong>Recent neurosurgery (Option D):</strong> Not a contraindication unless affecting hypothalamic-pituitary axis integrity or healing.</p>",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Atosiban </span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Follitropin </span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Leuprolide </span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Pegvisomant</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 4-year-old girl presented with hirsutism, breast enlargement, and a height and bone age consistent with that of a 9-year-old. Which of the following is the most appropriate drug for the treatment of this patient?</span></p>",
      "unique_key": "DT1166415",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166415,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical scenario indicates <strong>central precocious puberty</strong>, characterised by early sexual development with advanced bone age and secondary sexual characteristics.</p>\r\n<ul>\r\n<li>The most appropriate treatment is with <strong>continuous administration of a long-acting GnRH agonist such as leuprolide</strong>, which downregulates GnRH receptors in the pituitary, leading to decreased LH and FSH secretion and, hence, suppression of gonadotropin-dependent puberty.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510017ddd5bc0-f41d-4d81-81a6-2198b9605e19.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atosiban (Option A):</strong> Oxytocin receptor antagonist; used as a <strong>tocolytic agent</strong> for preterm labour, not used in precocious puberty.</p>\r\n<p><strong>Follitropin (Option B):</strong> Recombinant FSH used for <strong>infertility</strong> treatment by stimulating follicular development; it would <strong>worsen</strong> precocious puberty.</p>\r\n<p><strong>Pegvisomant (Option D):</strong> GH receptor antagonist; used in <strong>acromegaly</strong> to reduce IGF-1 levels; has <strong>no role</strong> in puberty regulation.</p>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Somatropin</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Desmopressin </span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Leuprolide </span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Octreotide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 47-year-old man presented with coarsened facial features, large hands and feet, and elevated serum IGF-1 levels. MRI revealed a large pituitary adenoma, and he underwent transsphenoidal surgery. However, hormone levels remain high postoperatively. Which of the following is the most appropriate next pharmacological treatment?</span></p>",
      "unique_key": "DT1166416",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166416,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Somatostatin analogues like <strong>octreotide</strong> are first-line pharmacologic agents used to treat acromegaly when surgery is not fully effective or not feasible.</p>\r\n<ul>\r\n<li>Octreotide acts by binding to somatostatin receptors, inhibiting growth hormone (GH) secretion and reducing IGF-1 levels.</li>\r\n<li>It also leads to <strong>tumour shrinkage</strong> in many patients with GH-secreting pituitary adenomas.</li>\r\n<li>It is given subcutaneously or in long-acting formulations (e.g., LAR 20&ndash;30 mg every 4 weeks).</li>\r\n<li>Octreotide is well-tolerated, with GI side effects (diarrhoea, abdominal pain, nausea) in up to 50% of cases.</li>\r\n<li>Approximately 25% of patients show <strong>tumour size reduction</strong>, and over 50% show <strong>symptom control</strong> and normalisation of IGF-1 levels.</li>\r\n<li>The medicines most often used to treat acromegaly are called somatostatin analogues (SSAs) like octreotide. These drugs curb the release of GH and may also reduce the size of the pituitary tumour. Several studies have shown that these drugs are safe and effective for long-term treatment.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Somatropin (Option A):</strong> Recombinant growth hormone; used for GH deficiency, not excess.</p>\r\n<p><strong>Desmopressin (Option B):</strong> Vasopressin analogue used in diabetes insipidus and haemophilia A; has no role in acromegaly.</p>\r\n<p><strong>Leuprolide (Option C):</strong> GnRH agonist; used in prostate cancer, endometriosis, and precocious puberty, not in GH excess.</p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Ovarian cancer</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Endometrial cancer</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardiotoxicity</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoporosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old woman comes to the physician for evaluation of a palpable mass in the left breast that she noticed 3 weeks ago. During this period, she has also had some left-sided blood-tinged nipple discharge. Biopsy confirms the diagnosis of lobular carcinoma in situ (LCIS) that is estrogen-receptor (ER) positive. The patient undergoes lumpectomy of the left breast, and hormonal therapy is started. The patient's therapy increases her risk of which of the following conditions?</span></p>",
      "unique_key": "DT1166417",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166417,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Tamoxifen increases the risk of endometrial cancer due to its partial agonist effect on estrogen receptors in uterine tissue.</p>\r\n<ul>\r\n<li>Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an <strong>estrogen receptor antagonist in breast tissue</strong> and as a <strong>partial agonist in endometrial tissue</strong>.</li>\r\n<li>In premenopausal women with ER+ breast cancer, <strong>tamoxifen is preferred</strong> due to its <strong>antagonist action on breast tissue</strong>, which reduces recurrence risk.</li>\r\n<li>However, in the <strong>endometrium</strong>, <strong>tamoxifen exhibits partial agonist effects</strong>, which lead to <strong>proliferative effects</strong> and <strong>increased risk of endometrial carcinoma</strong>, particularly with long-term use.</li>\r\n<li>This dual effect explains the paradox of tamoxifen: <strong>anti-estrogenic in the breast</strong>, <strong>estrogenic in the uterus</strong>.</li>\r\n<li>Raloxifene, in contrast, has <strong>no agonist activity on endometrial tissue</strong> and hence is <strong>not associated with this increased risk</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322e7f93082-da5b-48d9-888e-05329aa129b0.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Ovarian cancer (Option A):</strong> Tamoxifen may increase the incidence of ovarian cysts, but <strong>does not significantly increase</strong> the risk of ovarian cancer.</p>\r\n<p><strong>Cardiotoxicity (Option C):</strong> A known side effect of <strong>doxorubicin and trastuzumab</strong>, not tamoxifen. Tamoxifen <strong>does not cause cardiotoxicity</strong>.</p>\r\n<p><strong>Osteoporosis (Option D):</strong> Tamoxifen has <strong>agonist activity in bone</strong> and <strong>reduces the risk</strong> of osteoporosis in postmenopausal women.</p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Paclitaxel</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Raloxifene</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Palbociclib</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Exemestane</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old woman was diagnosed with metastatic breast cancer, for which she is currently receiving pharmacotherapy. A recent DEXA scan of the hip reveals a T-score of -2.8. Six months ago, her T-score was -1.7. Which of the following drugs is most likely responsible for this change in her bone mineral density?</span></p>",
      "unique_key": "DT1166418",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166418,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Exemestane</strong>, a steroidal aromatase inhibitor, reduces estrogen levels in postmenopausal women, leading to accelerated bone loss and osteoporosis.</p>\r\n<ul>\r\n<li>As given in the question, decreased bone density can occur during menopause due to a decrease in estrogen. However, the rapid decline in this patient's T-score suggests a drug-induced estrogen deficiency.</li>\r\n<li>Exemestane inhibits aromatase (CYP19A1), preventing the peripheral conversion of androgens to estrogen.</li>\r\n<li>It is commonly used as first-line endocrine therapy in postmenopausal women with ER+/PR+ metastatic breast cancer.</li>\r\n<li>The resulting hypoestrogenic state may lead to:\r\n<ul>\r\n<li>Vaginal dryness and dyspareunia (atrophic vaginitis)</li>\r\n<li>Accelerated bone loss and increased fracture risk<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100104969fd1-eada-449a-a84d-150c5659b192.png\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403229e2b7e47-3cb5-4502-ada8-d67e3ff7774e.jpg\"></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Paclitaxel (Option A):</strong> Microtubule stabilising agent used in breast cancer, but does not cause significant bone loss. Bone density changes are not characteristic of its side effect profile.</p>\r\n<p><strong>Raloxifene (Option B):</strong> A SERM that acts as an estrogen agonist on bone &rarr; protects bone mineral density &rarr; used to treat and prevent osteoporosis.</p>\r\n<p><strong>Palbociclib (Option C):</strong> A CDK4/6 inhibitor used in metastatic breast cancer; may cause cytopenias and fatigue, but does not directly reduce estrogen or affect bone density like aromatase inhibitors do.</p>",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">CuT (IUD)</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">COC</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Implanon</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Inj. DMPA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 24-year-old woman comes to the physician requesting advice regarding contraception. She was diagnosed with deep vein thrombosis 2 years ago. Her menses occur at regular 30-day intervals with normal flow. She is sexually active with one male partner and uses condoms inconsistently. A urine pregnancy test is negative. Which of the following is the most appropriate recommendation regarding contraception for this patient?</span></p>",
      "unique_key": "DT1166421",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166421,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>A copper intrauterine device (IUD) is the most appropriate choice for this patient due to her history of deep vein thrombosis, which is a contraindication for estrogen-containing contraceptives.</p>\r\n<ul>\r\n<li><strong>Copper IUD (CuT380A)</strong> is a long-acting, hormone-free intrauterine contraceptive that can be used safely in women with thromboembolic conditions. It has no systemic hormonal effects and provides reversible contraception for up to 10 years.</li>\r\n<li>It exerts its action primarily by producing an inflammatory reaction within the endometrium that impairs sperm viability, motility, and fertilisation.</li>\r\n<li>It is not associated with an increased risk of thromboembolic events.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322293fc355-4a53-451e-9fd8-98c3e5d022b4.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403255e792449-c287-4433-9086-9bf3d8748f97.jpg\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322b8db9e42-6899-4946-9137-dd4441a00548.jpg\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403229362aa27-3ac3-421d-9525-962d65de6944.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Combined oral contraceptive pills (COC) (Option B):</strong> Contain estrogen, which promotes clot formation and is contraindicated in patients with a history of venous thromboembolism.</p>\r\n<p><strong>Implanon (Option C):</strong> A progestin-only implant; while not containing estrogen, it should still be avoided or used with caution in thrombotic patients due to an unclear safety profile.</p>\r\n<p><strong>DMPA (Depot medroxyprogesterone acetate) (Option D):</strong> A long-acting injectable progestin. Although estrogen-free, caution is advised due to its association with adverse effects like irregular bleeding and reduced bone mineral density; data in thrombotic patients is limited.</p>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">CuT (IUD)</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">COC</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">POP</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Inj. DMPA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 21-year-old woman comes to you for advice for contraception. Her menses are painful and occur at regular 30-day intervals with heavy flow. Current medications include sumatriptan and iron supplements, which she has a hard time remembering to take. A urine pregnancy test is negative. The patient does not wish to become pregnant in the next 5 years. Which of the following is the most appropriate recommendation for contraception?</span></p>",
      "unique_key": "DT1166423",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166423,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>DMPA is the most suitable contraceptive in this patient due to its efficacy in treating menorrhagia, dysmenorrhea, and its estrogen-sparing profile, ideal for patients with migraine.</p>\r\n<ul>\r\n<li><strong>Medroxyprogesterone acetate (DMPA)</strong> is a long-acting injectable progestin administered every 3 months.</li>\r\n<li>It induces endometrial atrophy and anovulation &rarr; decreases menstrual blood loss and pain.</li>\r\n<li>Useful in <strong>iron deficiency anaemia</strong>, <strong>dysmenorrhea</strong>, and patients with <strong>migraine</strong> (where estrogen-containing contraceptives are contraindicated).</li>\r\n<li>Reduces the need for daily adherence &rarr; ideal for those with poor medication compliance.</li>\r\n<li>Also associated with reversible bone mineral density loss and delayed fertility return post-discontinuation.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510010d478d68-dcd9-4ccb-86a2-3040220ed6d4.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>CuT (Option A):</strong> Not preferred in this case because it may <strong>worsen dysmenorrhea and menorrhagia</strong>, although safe in migraine.</p>\r\n<p><strong>COC (Option B):</strong> Estrogen-containing pills are <strong>contraindicated in migraine</strong> due to increased stroke risk.</p>\r\n<p><strong>POP (Option C):</strong> While safe in migraine, <strong>strict timing adherence</strong> is required, not suitable for patients with poor compliance.</p>",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Flutamide</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">COC</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22-year-old woman comes to the physician because of bothersome hair growth on her face. She does not take any medications. She weighs 85 kg; her BMI is 32 kg/m<sup>2</sup>. Her serum follicle-stimulating hormone, luteinizing hormone, and testosterone are within the reference range. A urine pregnancy test is negative. Which of the following is the most appropriate pharmacotherapy at this time?</span></p>",
      "unique_key": "DT1166427",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166427,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Given a clinical scenario of excessive male pattern hair growth (hirsutism) with normal gonadotropins and testosterone levels without signs of further virilisation.</p>\r\n<ul>\r\n<li>This combination is highly suggestive of idiopathic hirsutism (IH).</li>\r\n<li>COCs are recommended as the first-line therapy for women with hirsutism due to their ability to reduce androgen levels.</li>\r\n<li>Estrogen-progestin contraceptives reduce androgen levels by suppression of circulating luteinizing hormone (LH) and stimulation of sex hormone-binding globulin (SHBG) levels.</li>\r\n</ul>\r\n<p>&nbsp;</p><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001a5974704-429e-4a9b-9250-c5cf1a5e4fa7.png\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325e200d770-11cc-4d67-8dbd-9fe70d7043f9.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Flutamide (Option A):</strong> May be used in IH but is a third-line anti-androgen reserved for refractory cases after &ge;6 months of other monotherapy.</p>\r\n<p><strong>Spironolactone (Option B):</strong> First-line anti-androgen in refractory moderate to severe hirsutism, not initial therapy.</p>\r\n<p><strong>Metformin (Option D):</strong> Used in PCOS to reduce insulin levels; not effective in idiopathic hirsutism.</p>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Finasteride</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Flutamide</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyproterone</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old man comes to the dermatologist for evaluation of progressive hair loss from his scalp. He first noticed the receding of the hairline over the bitemporal regions of his scalp 5 years ago. Since then, his hair has gradually become thinner over the crown of his head. Administration of which of the following drugs is most appropriate to treat this patient's hair loss?</span></p>",
      "unique_key": "DT1166429",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166429,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The patient has androgenetic alopecia, the most common cause of hair loss in adult males. Finasteride is a first-line agent that inhibits 5&alpha;-reductase, thereby reducing conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for follicular miniaturisation.</p>\r\n<ul>\r\n<li><strong>Finasteride</strong> 1 mg daily increases hair growth in men over a 2-year period.</li>\r\n<li>It improves hair density and slows the progression of hair loss.</li>\r\n<li>The drug is generally well tolerated but may cause sexual side effects such as decreased libido and erectile dysfunction.</li>\r\n<li><strong>Minoxidil</strong> (topical) is another first-line option that stimulates the anagen phase of the hair cycle.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032295545522-fb08-4823-97d4-d639e2405db4.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Flutamide (Option B):</strong> Non-steroidal antiandrogen; rarely used for hair loss due to hepatotoxicity risk and lack of evidence in male androgenetic alopecia.</p>\r\n<p><strong>Cyproterone (Option C):</strong> Antiandrogen and progestin; primarily used in female hirsutism and not suitable for male pattern hair loss.</p>\r\n<p><strong>Spironolactone (Option D):</strong> Potassium-sparing diuretic with antiandrogenic effects; used for hirsutism or androgenic alopecia in women, not men, due to risk of feminisation.</p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Kidney failure</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholestatic jaundice and elevation of SGPT</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Hirsutism</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperprolactinemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Rohan, a male athlete, uses large doses of anabolic steroids. He is at increased risk of which of the following?</span></p>",
      "unique_key": "DT1166433",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166433,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Athletes who administer high doses of anabolic steroids, such as 17&alpha;-alkylated androgens, are at increased risk of hepatotoxic effects, including <strong>cholestatic jaundice and elevated serum transaminases (SGPT)</strong>. These agents are known to cause hepatocellular damage and other hepatic dysfunction.</p>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322a78cec1e-a37a-4579-9c64-946bef96d8d1.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100115cc5c64-54d7-49a3-8110-89f776e35f89.png\"><br>\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322542a21f1-6306-411e-899f-e1b5538f4cb7.jpg\">",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Goserelin</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Medroxyprogesterone </span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Danazol</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Mifepristone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 27-year-old woman complains of abdominal pain at the time of menstruation. Laparoscopy findings are shown below. Which of the following is the most appropriate medical therapy for this patient?</span></p>",
      "unique_key": "DT1166438",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166438,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Medroxyprogesterone is preferred for the medical management of endometriosis-related pain due to its effective ovarian suppression via gonadotropin inhibition.</p>\r\n<ul>\r\n<li>The clinical scenario and laparoscopic image showing characteristic dark spots indicate <strong>endometriosis</strong>.</li>\r\n<li>For <strong>mild to moderate symptoms</strong>, first-line management includes <strong>NSAIDs</strong> and <strong>continuous hormonal contraceptives</strong>.</li>\r\n<li>When pregnancy is not desired, <strong>long-acting intramuscular medroxyprogesterone</strong> is effective for suppressing the hypothalamic-pituitary-ovarian axis by <strong>inhibiting gonadotropin release</strong>.</li>\r\n<li>This provides 3 months of ovarian suppression and is a commonly used therapeutic option.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510019d741437-63eb-4088-af5c-5e07521a0af0.png\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403221a8b3cd9-4613-4e3f-8a4c-78f863f2d041.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032287dcfbde-83d9-4bca-9861-4ef15dbcc32b.jpg\">",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Previous hysterectomy</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Atrophic vaginitis</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Family history of breast cancer </span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Hot flushes</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 54-year-old postmenopausal woman has low bone mineral density. You are considering therapy with raloxifene or HRT. Which of the following patient characteristics is most likely to lead you to select raloxifene?</span></p>",
      "unique_key": "DT1166440",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166440,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Raloxifene</strong> improves bone mineral density and reduces the risk of vertebral fractures, making it effective in osteoporosis. Importantly, it has estrogen antagonist activity in breast tissue and does not stimulate the endometrium, making it a safer alternative to HRT in patients with a family history of breast cancer.</p>\r\n<ul>\r\n<li><strong>Breast tissue</strong>: Raloxifene acts as an estrogen antagonist &rarr; reduces breast cancer risk (ideal for those with a family history).</li>\r\n<li><strong>Bone</strong>: Acts as an estrogen agonist &rarr; prevents bone loss and vertebral fractures.</li>\r\n<li><strong>Endometrium</strong>: Does not stimulate endometrial proliferation &rarr; safer than HRT for women with an intact uterus.</li>\r\n<li><strong>Hot flushes</strong>: May exacerbate vasomotor symptoms (not used if hot flushes predominate).</li>\r\n<li><strong>Atrophic vaginitis</strong>: Treated with local estrogen therapy, not raloxifene.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001bea632f1-d0f6-4bad-9b20-dd56115c652b.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Previous hysterectomy (Option A):</strong> HRT without progesterone can be used safely post-hysterectomy; raloxifene has no additional benefit in this context.</p>\r\n<p><strong>Atrophic vaginitis (Option B):</strong> Local estrogen is more effective than raloxifene; raloxifene has little to no vaginal estrogenic effect.</p>\r\n<p><strong>Hot flushes (Option D):</strong> Raloxifene may worsen vasomotor symptoms like hot flushes; HRT is preferred in symptomatic women.</p>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Glipizide</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Linagliptin</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Canaglifozin</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old man comes to the AIIMS OPD with a glomerular filtration rate (GFR) of 100 mL/min/1.73 m<sup>2</sup> and a glucose clearance rate of 96 mL/min. The consultant asks you which antidiabetic agent the patient is most likely taking.</span></p>",
      "unique_key": "DT1166567",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166567,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Correct Answer:</strong> <strong>C) Canagliflozin</strong></p>\r\n<p><strong>Explanation:</strong></p>\r\n<p>Glucose clearance nearly equal to GFR indicates that glucose is filtered but not reabsorbed, characteristic of SGLT2 inhibitor use, such as <strong>canagliflozin</strong>, which inhibits proximal tubule glucose reabsorption.</p>\r\n<ul>\r\n<li><strong>Normal physiology:</strong> Glucose filtered in the glomerulus is reabsorbed in the PCT via SGLT2 &rarr; normal glucose clearance &asymp; 0 mL/min</li>\r\n<li><strong>SGLT2 inhibitors:</strong> Block this reabsorption &rarr; filtered glucose is excreted unchanged &rarr; glucose clearance approaches GFR</li>\r\n<li><strong>Canagliflozin</strong> reduces plasma glucose and promotes renal excretion of glucose by inhibiting SGLT2 in PCT.</li>\r\n<li>Leads to <strong>osmotic diuresis</strong>, <strong>mild weight loss</strong>, and <strong>CV/renal benefit</strong></li>\r\n<li>The drug is <strong>contraindicated in advanced renal disease,</strong> as filtration is required for efficacy</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322b5f8f326-7ad9-47c6-8a82-bd3c5e4205d9.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322d6870d3e-2317-4f62-bca0-5acf3fe5bfac.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100121cf7428-dd44-4a2e-a41f-4ddd185ea0ae.png\">\r\n<p><strong>(Other options are ruled out)</strong></p>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}